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A b s t r a c t  
Dendrimers are considered the emerging polymeric architectures, known for their well defined 
molecular-weight, polydispersity, uniformity and high-surface functionality. These nano-architectures 
are capable of encapsulating low-high molecular-weight drug moieties in their interior or exterior 
through covalent bonding and host-guest interactions. Further, large surface volume made 
researchers to implicate dendrimers in biomedical and therapeutic applications. Regardless of the 
massive applications, sometimes its use is limited because of the cytotoxicity produced.  
Considering this, the present research is focused on the synthesis and PEGylation of citric acid 
dendrimers. PEGylation is an act of conjugating polyethylene glycol to dendrimers that completely 
eliminates the toxicity issues associated with dendrimers and render them biocompatible. Cytarabine 
was loaded in the dendritic architecture to target specifically the tumor cells. Dendrimers are made 
tumor specific by incorporating certain agents that get cleaved in tumor environment. Synthesized 
dendrimers were studied for its effect on acute cytotoxicity, tissue-distributions and pharmacokinetic 
parameters. 
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Introduction 
Dendrimers represent a novel type of polymeric material, 
characterized by its repetitive branching, definite molecular weight, 
shape, size and uniform distribution.  Its degree of control over 
molecular weight and shape gained interest of many researchers for 
encapsulation and drug delivery properties [1]. The nanosize of 
dendrimers facilitates the delivery of drug molecules to the target 
site, tumor cells through enhanced permeation and retention effect 
[2]. Drug molecules get conjugated to the dendritic system via 
physical attachment to the dendritic core or by covalent conjugation 
to the dendritic surface. Molecular moieties can be loaded both to 
the interior and exterior surface of the dendrimers [3]. A number of 
linker technologies have been investigated till date, but only 
dendrimers provide tumor specific drug release via incorporating 
acid labile hydrazones, esters and peptides that get cleaved by the 
enzymes present in the tumor environment [4]. When compared to 
other nano carriers, relatively small size of dendrimers enables 
them to get cleared off from the body via kidneys and escape 
phagocytosis by RES uptake [5]. Considering the use of dendrimers 
as carriers, it is essential that they should be bio-compatible and 
non-toxic [6].  
Among different dendrimers available today, citric acid dendrimers 
are more biocompatible, water soluble and relatively less toxic [7]. 
Presence of multiple functional end groups at its terminal surface 
enables citric acid dendrimers to entrap a variety of molecules such 
as imaging agents, therapeutic agents, contrasting agents, targeting 
moieties etc [8]. Usually, biomolecules either get entrapped into the 
interior or get complexed to the exterior of dendrimers [9]. Drug- 
dendrimer interaction and water solubility are the two factors 
governing drug retention and its successive release from the host, 
dendrimers [10]. Being water-soluble, citric acid dendrimers prolong 
the half-life of encapsulated drugs. They take advantage of EPR 
effect which is commonly observed with tumor cells. Blood vessels 
of tumors are poorly aligned and possess proliferations in its 
structure [11]. Owing to this property of tumor cells, nano sized 
dendrimers easily pass into them without disturbing other healthy 
cells. Because of poor lymphatic drainage, dendrimers accumulate 
in tumor cells for a longer time to release the encapsulated drug into 
them, which simultaneously exhibit therapeutic activity and stand 
responsible for its destruction [12].  
Cytarabine, an antineoplastic agent is found effective against 
cancers like acute myeloid leukemia, melanoma etc. In the present 
study, an attempt has been made to formulate PEGylated citric acid 
dendrimers and characterize them for different parameters like MTT 
assay, tissue distribution studies and Pharmacokinetic studies. 
 
Materials and methods 
 
Materials 
 
Cytarabine was procured from Yarrow Chemicals, Mumbai; 
potassium permanganate, sodium carbonate, thionyl chloride, 
dimethyl form amide, pyridine, diethyl ether and N, N’- dicyclohexyl 
carbodiimide were purchased from Sd Fine Chemicals Ltd., 
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Mumbai; polyethylene glycol 400 and chloroform were purchased 
from Finar Chemicals Pvt. Ltd. Ahmadabad. All the chemicals used 
were of good analytical grade. * 
 
Animals 
 
Balb/c mice were purchased from National Institute of Nutrition 
(NIN), Hyderabad for their use in tissue distribution and cytotoxic 
studies. All the animals were inbred for experimental purposes in 
accordance with CPCSEA guidelines. Animals were housed in 
individually ventilaged cage system with a 12hr light/dark cycle. 
Noise, temperature and humidity were controlled as per the 
guidelines. They were supplied with standard rodent chow, water 
and bedding material before surgery. 
 
Cell lines 
 
B16F10 melanoma and K562 myeloid cell lines were procured from 
American Type Culture Collection (ATCC) and cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 
10% FCS. 
 
Method of Preparation 
 
Citric acid dendrimers were prepared using Divergent technique and 
the steps involved in its synthesis are: 
Synthesis of 5 generations of citric acid dendrimers 
PEGylation of synthesized dendrimers 
Drug loading of the PEGylated dendrimers 
 
Synthesis of 5 generations of Citric acid dendrimers 
Dendrimers synthesis can be conveniently studied in 3 steps 
Step 1: 35.5gms of Potassium permanganate was dissolved in 
694ml of water in a beaker, simultaneously; 3.75gms of Sodium 
carbonate was dissolved in 38ml of water in another beaker. The 
two solutions were mixed together with continuous stirring and 
110ml of Polyethylene glycol was added and stirred on a magnetic 
stirrer for 3-4hrs to give out a homogenous mixture. The resultant 
mixture was filtered and the collected filtrate was heated on a 
mantle at 60-70°C with random cooling in between. This heating and 
cooling process was continued till a 100ml concentrated liquid 
retains. Resultant concentrate was covered with a layer of ether. 
Aqueous layer was separated out using a separating funnel and 
heated on a mantle at 70°C for the complete removal of ether. A 
white precipitate of Polyethylene glycol di acid formed is collected 
and is referred to as a 1st generation dendrimer.  
Step 2: To synthesize a second generation dendrimer, 
dendrimer of 1st generation was made to react with Thionyl chloride 
in a round-bottomed flask provided with a condenser. This assembly 
was set on a magnetic stirrer for an hour and heated on a mantle at 
70°C to yield chlorinated polyethylene glycol, a G1.5 dendrimer. 
Obtained dendrimer was dissolved in 20ml of Dimethyl Formamide 
and refrigerated for 24hrs on an ice-bath. On the other side, 
required amount of citric acid was dissolved in a beaker containing 
10ml of DMF, followed by the addition of 110ml of pyridine. Both the 
reaction mixtures were placed on an ice-bath in a refrigerator 
overnight. After 24hrs, the solutions were taken out, mixed with 
each other and incubated for 6hrs at 55-60°C in an incubator to 
yield a second generation dendrimer. The resultant dendrimer was 
further purified by Column Chromatography technique [13]. 
2nd generation dendrimer was repeated with step 2 with increasing 
quantities of citric acid and thionyl chloride to produce a 4 
generation dendrimer as shown in table-1. 
 
Table-1: Formulation of Dendrimers 
Formulation KMNO4 Na2co3 PEG400 Thionyl chloride Citric acid Pyridine DMF Drug  
F1(G1) 35.5gm 3.75gm 110ml - - - - - 
F2(G2) 35.5gm 3.75gm 110ml 6ml 0.1g 100ml 30ml 100mg  
F3(G3) 35.5gm 3.75gm 110ml 8ml 0.2gm 100ml 30ml 100mg 
F4(G4) 35.5gm 3.75gm 110ml 10ml 0.4gm 100ml 30ml 100mg 
 
PEGylation of dendrimers 
 
Conjugation of polyethylene glycol to the dendrimers is called 
PEGylation. It is considered an important step in building of 
dendrimers as they impart stability to the drug incorporated within 
them with reduced side-effects and drug leakage from the carrier 
system [14]. 
For PEGylation, 1 mole of above synthesized dendrimers was 
dissolved in 10ml of DMF completely in a conical flask. N, N’ 
Cyclohexyl carbodimide was added and the mixture was set 
undisturbed for 4 days at 40ºc. To this reaction mixture, 85ml and 
150ml of polyethylene glycol and chloroform were added 
respectively to yield a clear solution and refluxed for 3-4 days. The 
resultant was filtered through a separating funnel by adding 5ml of 
water that completely removes the unreacted N, N’- dicyclo hexyl 
carbodimide [15]. 
 
Drug loading in the PEGylated dendrimers 
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Cytarabine was dissolved in distilled water, added to PEGylated 
dendritic solution and stirred on a magnetic stirrer for 24hrs for 
complete encapsulation of drug into dendrimers [13].  
 
Characterization of synthesized PEGyalted dendrimers 
 
Prepared dendrimers were characterized for the following 
parameters: 
 
MTT cytotoxicity assay 
 
MTT Assay was performed to determine the cytotoxicity of 
synthesized dendrimers. For this B16F10 melanoma cells and K562 
myeloid cells were selected and seeded in 96-well plates at a 
density of 4.5x103cells/well separately. On the other side, 
dendrimers were dissolved in some suitable solvent like DMSO and 
added to the well plates. Final concentration of dendrimers was 
adjusted to 0.001 to 10 µg/ml concentration range and incubated at 
370c for 96hrs and the media was discarded. Each well was 
supplied with 100µl of MTT solution and incubated for 4hrs. Cells 
proliferate to produce blue colored formazon crystals, dissolved in 
DMSO under safety cabinet and placed in an orbital shaker for 10 
minutes at room temperature. Finally absorbance of the above was 
recorded at 550nm by a micro plate reader [16]. 
 
Tissue distribution studies 
 
Tissue distribution studies aim at studying the amount of drug being 
distributed to various body organs. Healthy balb/c mice were 
selected and B16F10 cell lines were injected subcutaneously. Later, 
the animals were sacrificed and the developed tumors were 
propagated in sufficient number of experimental animals.  
Animals with 100mm3 tumor were selected, starved overnight and 
administered with 10mg/ml of synthesized drug-dendrimer complex 
through tail vein. Such animals were sacrificed at different time 
intervals like 10, 30, 60, 120 and 180 minutes after injection. 
Organs like spleen, liver, kidney and lungs along with tumor were 
isolated, washed with distilled water, weighed, and homogenized to 
1 g/ml of tissue homogenate in PBS. Thus obtained homogenates 
were centrifuged at 1000rpm and the supernatants were analyzed 
using HPLC [17]. 
 
Pharmacokinetic studies 
 
Pharmacokinetic studies were performed to know the drug’s 
bioavailability and parameters such as T max, C max etc. B16F10 
mice were chosen as model animals for pharmacokinetic studies. 
Animals under study were starved overnight. Control group was 
provided with saline and test was fed with dendrimer drug 
formulations orally. Throughout the course of experiment, water was 
supplied both for the control and test groups. Blood samples were 
collected at fixed time intervals like 0, 15, 30, 60, 120 and 180 
minutes respectively and centrifuged for 10 minutes at 20000rpm. 
Supernatant plasma layer was separated and analyzed under 
HPLC. Data obtained was represented in terms of graphs against 
time (Hemmer, et al., 2013).  
 
Results and discussion 
 
MTT assay 
 
MTT assay was performed against B16F10 and K562 cell lines to 
determine the acute cytotoxicity. As per the results, drug, cytarabine 
concentration in drug-dendrimer complex was adjusted in the range 
0.001 to 10µg/ml. At 0.001µg/ml, inhibition of cellular proliferation 
was found to be 2.47% and at 10 µg/ml, 51.39% (from figures 1 and 
2).From the results, it is estimated that the cytotoxicity of formulated 
dendrimers is a result of interaction between dendrimers and cell 
surfaces. And as dendrimer generation increases, cytotoxic effect of 
dendrimers also increases significantly. A fifth/fourth generation 
dendrimer exhibits stronger cytotoxicity as compared to lower 
generations. As bulk of dendrimer increases, capability of a 
dendrimer to interact with its surrounding cells also increases 
gradually 
. 
 
Table-2: Tabular representation of MTT assay results against B16F10 cells lines induced balb/c albino mice 
Concentration DCYT G4D.CYT G5D 
10 53.44 51.39 10.58 
1 36.48 31.47 11.64 
0.1 21.48 22.85 2.39 
0.01 6.76 18.19 1.28 
0.001 2.44 2.47 2.17 
IC50value µg/ml 10 10 >100 
DCYT= Drug cytarabine; G4D.CYT= 4th generation drug loaded dendrimer; G5D= 5th generation plain dendrimer. 
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                                                      X Axis: Concentration ug/ml 
                 Y Axis: Percentage Inhibition 
Figure-1: Graphical representation of MTT assay results for the drug Cytarabine for B16F10 cell lines induced balb/c albino mice 
 
Table-3: Tabular representation of MTT assay results against K562 cell lines induced albino balb/c mice 
Concentration DCYT G4D.CYT G5D 
10 56.98 54.63 8.85 
1 54.21 48.71 7.44 
0.1 23.98 18.52 5.21 
0.01 5.47 17.44 6.47 
0.001 3.28 3.25 3.87 
IC50value µg/ml 0.6 1 >100 
 
X Axis: Concentration ug/ml 
 Y Axis: Percentage Inhibition 
Figure-2: Graphical representation of MTT assay results for drug Cytarabine for K562 cell lines induced balb/c albino mice 
 
Tissue distribution studies 
 
Balb/c mice were used for studying tissue distributions of 
cytarabine. Soon after administering the drug, animals were 
sacrificed to study drug distribution pattern to various body organs. 
Tissue distributions of the drug, cytarabine by different organs is 
presented in figure 3 and as per the results of the study, tumor 
uptake of cytarabine increases significantly with time and was 
maximum at 180th minute i.e., 12.8µg/ml. The suggested 
mechanism for the uptake of cytarabine was supposed to be EPR 
effect. Enhanced permeability and retention due to poorly aligned 
blood vessels and poor lymphatic drainage respectively enables the 
drug cytarabine to interact with the tumor cells and exhibit its action. 
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Table-4: Tabular representation of tissue distribution study data in Tumor (µg/ml) 
 
Distribution time 
(min) 
10 30 60 120 180 
DCYT 5.33  6.09  10.3  12.47  13.21  
G4D.CYT 7.10  8.90  13.36  12.59  12.8  
G5D 0 0 0 0 0 
 
Table-5: Tabular representation of tissue distribution study data in Lungs (µg/ml) 
 
Distribution time 
(min) 
10 30 60 120 180 
DCYT 5.33  4.14  7.75  12.90  12.47  
G4D.CYT 6.85  9.95  12.17  12.50  13.58  
G5D 0 0 0 0 0 
 
Table-6: Tabular representation of tissue distribution study data in Liver (µg/ml) 
 
Distribution time 
(min) 
10 30 60 120 180 
DCYT 4.02 5.23 10.06 11.7 12.50 
G4D.CYT 4.93 8.84 14.3 12.48 14.4 
G5D 0 0 0 0 0 
 
Table-7: Tabular representation of tissue distribution study data in Kidney (µg/ml) 
 
Distribution time 
(min) 
10 30 60 120 180 
DCYT 5.27 6.13 9.75 12.48 12.50 
G4D.CYT 7.07 10.06 13.53 13.20 12.92 
G5D 0 0 0 0 0 
 
Table-8: Tabular representation of tissue distribution study data in Spleen (µg/ml) 
 
Distribution time 
(min) 
10 30 60 120 180 
DCYT 4.65 5.37 9.95 13.36 13.7 
G4D.CYT 5.15 8.52 13.20 13.72 13.12 
G5D 0 0 0 0 0 
 
Table-9: Tabular representation of tissue distribution study data for plasma  
 
Distribution time 
(min) 
10 30 60 120 180 
DCYT 30.61 30.58 10.42 6.00 4.89 
G4D.CYT 28.52 24.3 10.20 7.34 6.11 
G5D 0 0 0 0 0 
 
 
 
 
 
 
 
            
Figure-3: Graphical representation of tissue distribution study results for drug Cytarabine on a
 
Pharmacokinetic studies 
 
Pharmacokinetic studies aim at quantifying the amount of drug 
released from the formulations after the IV administration of drug
dendrimer complex. From the results, C max of the drug
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(a)                                                            (b) 
(c)                                                     (d) 
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) tumor, b) lungs, c) liver, d) 
f) plasma 
-
-dendrimer 
complex and drug are 28.51 and 30.61 µg/ml respectively and 
figure 4 below shows the mean plasma concentration 
of cytarabine after its IV administration. AUC at the end of 30 
minutes is 24.33 µg/ml.  
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Figure-4: Mean plasma concentration – time curve of cytarabine 
 
Conclusion 
 
Dendrimers are an effective means for delivering a drug especially 
an antitumor drug to the tumor cells. In the present work, an attempt 
has been made to formulate PEGylated dendrimers. The 
synthesized dendrimers were characterized for MTT assay, tissue 
distributions and pharmacokinetic studies. Results from various 
studies proved that dendrimers are safe and strong enough for 
delivering the drug at the target site. During the study, it was found 
that dendritic generations play a major role. Higher generations 
have a greater impact on study parameters over lower generations.  
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